Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tools for measuring clinical effectiveness.

Dieter Naber1, Antonio Vita

  • 1Department of Psychiatry and Psychotherapy, University of Hamburg, Hamburg, Germany. naber@uke.uni-hamburg.de

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|December 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutritional Influences on the Brain in ADHD: Evidence from Neuroimaging Studies.

Neurology international·2026
Same author

Symptom profiles at baseline are associated with remission in major depression: a confirmatory analysis of the PANDORA trial.

Journal of psychiatric research·2026
Same author

Correction: A narrative review on trazodone as a multimodal and multifunctional antidepressant: clinical relevance of formulations, dosing, and pharmacokinetic/pharmacodynamic targets.

Annals of general psychiatry·2026
Same author

Artificial Intelligence in Schizophrenia Spectrum Disorders: Current Use and Future Perspectives. A Systematic Mapping Literature Review.

Alpha psychiatry·2026
Same author

A narrative review on trazodone as a multimodal and multifunctional antidepressant: clinical relevance of formulations, dosing, and pharmacokinetic/pharmacodynamic targets.

Annals of general psychiatry·2026
Same author

Internalized Stigma Predicts Life Engagement in People With Schizophrenia: A Cross-Sectional Observational Study in a Real-World Setting.

The International journal of social psychiatry·2026

Current schizophrenia treatment studies overlook key effectiveness factors. This research proposes six outcome domains and the revised Global Outcome Assessment of Life in Schizophrenia (GOALS) scale to better evaluate schizophrenia treatment effectiveness.

Area of Science:

  • Psychiatry and Mental Health
  • Clinical Effectiveness Research
  • Schizophrenia Treatment Outcomes

Background:

  • Efficacy studies for schizophrenia treatments often neglect crucial aspects influencing overall clinical effectiveness.
  • Existing rating scales inadequately assess the multifaceted nature of schizophrenia outcomes.
  • A comprehensive approach is needed to evaluate treatment effectiveness beyond symptom reduction.

Purpose of the Study:

  • To propose six essential domains for assessing schizophrenia clinical effectiveness: disease symptoms, tolerability, functioning, well-being, burden, and adherence.
  • To highlight the limitations of current specialized rating scales in measuring comprehensive treatment outcomes.
  • To advocate for the development and validation of new instruments, such as the revised Global Outcome Assessment of Life in Schizophrenia (GOALS) scale.

Related Experiment Videos

Main Methods:

  • Definition of six distinct outcome domains contributing to schizophrenia clinical effectiveness.
  • Critique of existing rating scales for their narrow focus on specific schizophrenia aspects.
  • Proposal for the development of new rating instruments covering all defined domains.

Main Results:

  • Identification of six key domains: symptoms, tolerability, functioning, well-being, family/career burden, and treatment adherence.
  • Demonstration that current scales are insufficient for measuring comprehensive clinical effectiveness in schizophrenia.
  • Introduction of the revised Global Outcome Assessment of Life in Schizophrenia (GOALS) scale as a potential comprehensive measure.

Conclusions:

  • Further development of the GOALS scale is recommended, including long-term validation and patient perspective integration.
  • Clinician education on scoring the GOALS scale is crucial for its effective implementation.
  • Adoption of a multi-domain approach to evaluating schizophrenia treatment outcomes will enhance clinical decision-making.